PPA News


111 Articles found
Page 1 of 12 • Next

Posted by: Matthew Helms on Nov 6, 2020

 

The Research Committee is accepting grant applications in the areas of neonatal and pediatric research. 

NEONATAL PHARMACY SMALL RESEARCH GRANT 

The Neonatal Pharmacy Resident/Fellow Research Grant supports research in neonatal medication use conducted by pharmacy residents (e.g., PGY-1, PGY-2 pediatric pharmacy resident) and fellows. The primary purpose of the research award is to improve safe and effective use of medications in neonates. Research projects can comprise a wide range of medication-use topics, including but not limited to: technology, safety, and/or pharmacotherapy. A secondary goal of the program is to develop and strengthen the skills of pharmacy residents and fellows by fostering development of mentoring relationships with more experienced senior investigators.

The $2,000.00 grant(s) provide funding for specific neonatal research related to medication use and are not intended for long-term support of research programs.

The application deadline is December 20, 2020

For more information and to apply, please direct your browser to: https://www.ppag.org/?pg=NeonatalSmallGrant


PEDIATRIC PHARMACY SMALL RESEARCH GRANT - NEW PROGRAM

The Pediatric Pharmacy Resident/Fellow Research Grant supports research in pediatric medication use conducted by pharmacy residents (e.g., PGY-1, PGY-2 pediatric pharmacy resident) and fellows. The primary purpose of the research award is to improve safe and effective use of medications in pediatric patients. Research projects can comprise a wide range of medication-use topics, including but not limited to: technology, safety, and/or pharmacotherapy. A secondary goal of the program is to develop and strengthen the skills of pharmacy residents and fellows by fostering development of mentoring relationships with more experienced senior investigators.

The $2,000.00 grant(s) provide funding for specific pediatric research related to medication use and are not intended for long-term support of research programs.

The application deadline is December 20, 2020

For more information and to apply, please direct your browser to: https://www.ppag.org/?pg=PediatricSmallGrant

Posted by: Shannon Manzi on Sep 10, 2020

Access to childhood vaccines, and in turn the protection offered to the greater public health, is critical to the health and welfare of our country. PPA strongly endorses the action taken by the Secretary of Health and Human Services under the Third Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID–19, allowing for the provision of childhood vaccines by pharmacists. PPA stands with our fellow pharmacists to ensure competency, education of the public, transparent communication and continued partnership with our provider colleagues.

Shannon Manzi, PharmD, BCPPS, FPPA
President, Pediatric Pharmacy Association

 

 

Posted by: Matthew Helms on Jun 2, 2020

 

On Thursday, May 28, 2020 after thoughtful consideration, the Board voted to shift our 2020 Fall Conference and BCPPS Review and Recertification Course to a virtual format. Many factors contributed to our decision. 

The most important contributing factor is the health of our members and staff during the COVID-19 pandemic. We also recently surveyed you, our members, to ask about the effects the pandemic has had on your employers and your personal feelings about traveling at this time.

The vast majority of our members work in institutions that have enforced indefinite business-related travel bans or restrictions. Some of you may not be able to travel for the rest of the year. Also, most of our members' employers have already or will experience a reduction in their travel budgets for the foreseeable future. In addition, and maybe most importantly, survey participants indicated they are uncomfortable traveling to an in-person conference even if the challenges listed above were mitigated. 

We are also concerned about the logistical challenges and liability of conducting an in-person event during a global pandemic. 

While we were hopeful that we could offer a hybrid event, the uncertainty is too great to plan any in-person gathering in good conscience. While we are disappointed that will not meet in-person this year, we are not disheartened, and we look forward to working on offering an interactive, 100% virtual event. 

We learned much from conducting our Annual Meeting virtually. We have listened to the feedback of the 500+ participants, and we will be improving and adjusting the Fall Conference experience to make it even better. Here is what we have in store for the Fall Conference this year: 

  1. Twenty hours (20) of continuing pharmacy education in the areas of GI/Nutrition, General Pediatrics and Preceptor Development, including eight (8) hours of BCPPS recertification credit. 
  2. Poster Session 
  3. Residency Showcase 
  4. Helms Award Lecture
  5. Yaffe Award Lecture
  6. Lobby Lunch Sessions (an opportunity each day to interact with your friends and colleagues virtually). 
  7. Exhibitor Theaters
  8. And don’t forget, the 20-hour BCPPS Review and Recertification Course

 

We have reduced our registration fees (up to 30%) to make our Conference even more accessible in the light of your current budget challenges. If you are an individual member of PPA, you can register for the entire conference for $300. That's $15 per credit hour. And it’s even more affordable for residents and students! Also, we have eliminated regular and late registration fees. Every rate is an early bird rate! We, of course, encourage you to register early.

You can still submit YOUR proposal(s) and/or abstract(s) to be considered for the Fall Conference. 

Call for Education Program Proposals - All educational programs at PPA are sourced by our members, who submit proposals to be considered by the Education Committee.

We call upon our members to submit ideas for sessions in GI/Nutrition, General Pediatrics, and Preceptor Development or Scholarship. You may submit a full proposal (which includes title, speakers, learning objectives, learning methods, and educational needs assessment), or you can submit a partial proposal (which includes suggested title, speakers, and learning objectives). Please note that all proposals will be considered for our PPA-U BCPPS recertification program.

The proposal deadline is June 26, 2020. Submit Proposal

Call for Abstracts. All practitioners, investigators, post-doctoral trainees, and students in the field of pediatric clinical pharmacy, whether members of PPA or not, are invited to submit abstracts of papers to be considered for platform or poster presentation at the Fall Conference. Poster Presentations are informal discussions of current projects in pharmacy practice with meeting attendees. It is your opportunity to share your research or successful programs that have worked in pediatric healthcare systems, and to pick up ideas from others.

NOTE FOR DEFERRED ANNUAL MEETING ABSTRACTS: You must re-submit your abstract using the Fall Conference Abstract submission site.

The abstract deadline is June 26, 2020. Submit Abstract

We appreciate your input as members of PPA and look forward to coming together as a community and professional family for the 2020 PPA Fall Conference and BCPPS Review and Recertification Course

Thank you for your ongoing strong commitment and dedication to your patients, family, and communities. You are what make PPA and the profession of pediatric pharmacy AWESOME!

Sincerely, 

Hanna Phan, PharmD, FCCP, FPPA
President (2019-2020)

Matthew Helms, MA, CAE
Executive Director

 

Posted by: Shannon Manzi & Matthew Helms on Nov 3, 2020

The 30th Annual PPA Meeting is going virtual (AGAIN!).  Although we will miss being in beautiful Norfolk, VA in the Spring of 2021, we hope to get there soon! The dates of the Annual Meeting will be moving to Wednesday, April 21 to Sunday, April 25, 2021 to be consistent with our traditional Annual Meeting schedule.

The Board of Directors based this decision on many factors. First and foremost, the health and wellbeing of our members and attendees will always be at the forefront of our decision making process. Secondly, we are aware of departmental travel and budget restrictions that many of you face in the wake of the pandemic. PPA has successfully hosted two virtual conferences, and we are confident we will be able to once again provide an excellent continuing education opportunity and meeting experience for our members.

Regardless of the delivery method, we are committed to providing CE and BCPPS recertification sessions in the areas of infectious disease and pediatric intensive care. We will also be conducting a virtual poster session and residency presentations, which have been very well rated during our previous virtual conferences. And like the Fall Conference, we will be adding round table discussions, committee meetings, and social events to the agenda!

Registration information will be posted on the PPA website soon.

We have also re-opened the Call for Education Proposals. You now have until Friday, November 6, 2020 to submit your proposal. Click here.

Thank you for your ongoing support of and contributions to your PPA. Although these are challenging times, we continue to be enthusiastic about our virtual conferences. We look forward to “seeing” you there.

Posted by: Matthew Helms on Oct 26, 2020

On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved VEKLURY (remdesivir) for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. VEKLURY should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Perform renal and hepatic laboratory testing and assess prothrombin time in all patients before initiating VEKLURY and during treatment as clinically appropriate.

The approved recommended dosage of VEKLURY in adults and pediatric patients 12 years of age and older and weighing at least 40 kg is a single loading dose of VEKLURY 200 mg on Day 1 followed by once-daily maintenance doses of VEKLURY 100 mg from Day 2 infused over 30 to 120 minutes. For patients not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO), the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. For patients requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days.

Additional information regarding dosage and administration as well as warnings and precautions about hypersensitivity including infusion-related and anaphylactic reactions, increased risk of transaminase elevations, and risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate can be found in the full prescribing information linked below.

Mechanism of Action (MOA) and Pharmacokinetics (PK)

MOA: Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

PK: The PK properties of remdesivir and metabolites are provided in Table 1. The multiple dose PK parameters of remdesivir and metabolites in healthy adults are provided in Table 2.

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

Use in Specific PopulationsDrug Interactions

Concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended due to antagonism observed in cell culture. Drug-drug interaction trials of VEKLURY and other concomitant medications have not been conducted in humans.

Pharmacokinetic differences based on sex, race, or age on the exposures of remdesivir have not been evaluated.

Renal Impairment: The pharmacokinetics of VEKLURY have not been evaluated in patients with renal impairment. Determine eGFR in all patients before starting VEKLURY and monitor while receiving VEKLURY as clinically appropriate. VEKLURY is not recommended in patients with eGFR less than 30 mL per minute because the excipient betadex sulfobutyl ether sodium is renally cleared and accumulates in patients with decreased renal function. Patients with eGFR greater than or equal to 30 mL per minute have received VEKLURY for treatment of COVID-19 with no dose adjustment of VEKLURY.

Hepatic Impairment: The pharmacokinetics of VEKLURY have not been evaluated in patients with hepatic impairment. Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate.

Pediatric Patients: The pharmacokinetics of VEKLURY in pediatric patients have not been evaluated. Using modeling and simulation, the recommended dosing regimen is expected to result in comparable steady-state plasma exposures of remdesivir and metabolites in patients 12 years of age and older and weighing at least 40 kg as observed in healthy adults.

Efficacy and Safety

Subjects with Mild/Moderate and Severe COVID-19: Efficacy of VEKLURY was demonstrated in a randomized, double-blind, placebo-controlled clinical trial of hospitalized adult subjects with confirmed SARS-CoV-2 infection and mild, moderate, or severe COVID-19 compared treatment with VEKLURY for 10 days with placebo. The primary clinical endpoint was time to recovery within 29 days after randomization.

Pediatrics: The safety and effectiveness of VEKLURY for the treatment of COVID-19 have been established in pediatric patients 12 years and older and weighing at least 40 kg. Use in this age group is based on extrapolation of pediatric efficacy from adequate and well-controlled studies in adults. Clinical trials of VEKLURY included 30 adult subjects weighing 40-50 kg. The safety in this weight group was comparable to adult subjects weighing greater than 50 kg. Thirty-nine pediatric patients 12 years and older and weighing at least 40 kg received VEKLURY in a compassionate use program; the available clinical data from these patients are limited. The safety and effectiveness of VEKLURY have not been established in pediatric patients younger than 12 years of age or weighing less than 40 kg.

Additional information regarding the efficacy trials can be found in the full prescribing information linked below.

The most common adverse reactions (incidence greater than or equal to 5%, all grades) observed with treatment with VEKLURY are nausea, ALT increased, and AST increased.


Full prescribing information is available at https://go.usa.gov/x7YVW.

Visit Drugs@FDA at http://go.usa.gov/cMsjT for prescribing and patient information, approval letters, reviews and other information for FDA-approved drug products, which are often available shortly following approval.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at https://www.fda.gov/safety/medwatch/default.htm, by faxing (1-800-FDA-0178), or by mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at https://updates.fda.gov/subscriptionmanagement (note: this link does not work with Internet Explorer) and select Clinical Pharmacology Corner under Drugs.

We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

Posted by: Matthew Helms on Oct 7, 2020

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

On September 29, 2020, the U.S. Food and Drug Administration (FDA) approved efficacy supplements for SIMPONI ARIA for patients 2 years of age and older for the treatment of active psoriatic arthritis (PsA) or active polyarticular juvenile idiopathic arthritis (pJIA). In addition to the treatment of children ages 2 years and older with active pJIA or active PsA, SIMPONI ARIA is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, active PsA, or active ankylosing spondylitis (AS).

The approved recommended dosage of SIMPONI ARIA is:

  • Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.
  • Pediatric patients with polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.

Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA. Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis. Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member.

Additional information regarding dosage and administration as well as warnings and precautions about serious infection, invasive fungal infections, hepatitis B reactivation, malignancies, congestive heart failure, demyelinating disorders, autoimmunity, use with anakinra or abatacept, switching between biological disease modifying antirheumatic drugs, hematologic cytopenias, vaccinations/therapeutic infectious agents, or hypersensitivity reactions can be found in the full prescribing information linked below.

Mechanism of Action (MOA), Pharmacokinetics (PK), and Pharmacodynamics (PD)

MOA: Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα.

General PK: Golimumab exhibited approximately dose-proportional pharmacokinetics in patients with RA over the dose range of 0.1 to 10.0 mg/kg (0.05 to 5 times the approved recommended adult dosage) following a single intravenous dose.

Absorption: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, a mean Cmax of 44.4 ± 11.3 mcg/mL was observed in patients with RA. Data directly comparing 2 mg/kg intravenous administration and 50 mg subcutaneous administration are not available.

Distribution: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the mean volume of distribution was estimated to be 115 ± 19 mL/kg in healthy subjects, and 151 ± 61 mL/kg in patients with RA. The volume of distribution of golimumab may indicate that golimumab is distributed primarily in the circulatory system with limited extravascular distribution.

Elimination: Following a single intravenous administration of 2 mg/kg SIMPONI ARIA, the systemic clearance of golimumab was estimated to be 6.9 ± 2.0 mL/day/kg in healthy subjects and 7.6 ± 2.0 mL/day/kg in patients with RA. The mean terminal half-life was estimated to be 12 ± 3 days in healthy subjects and the mean terminal half-life in RA patients was 14 ± 4 days.

PD: Following treatment with SIMPONI ARIA in patients with RA, decreases from baseline were observed in tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3), resistin, interleukin-6 (IL-6), macrophage inflammatory protein-1 (MIP-1b), vascular endothelial growth factor (VEGF), serum amyloid A (SAA), S100A12, and high sensitivity C-Reactive protein (hsCRP). Conversely, increases from baseline were observed in tartrate-resistant acid phosphatase (TRAP-5b). The clinical relevance of this information is not known.

Immunogenicity: Antibodies to golimumab were detected in 13 (3%) golimumab-treated patients following IV administration of SIMPONI ARIA in combination with MTX through Week 24 of Trial RA, of which all were neutralizing antibodies. Through approximately 6 months, the incidence of antibodies to golimumab for RA, PsA, AS, and pJIA was 21%, 19%, 19% and 31%, respectively. Where tested, approximately one-third to one-half were neutralizing. Patients with RA, PsA, AS and pJIA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab. The immune response effect on golimumab clearance in patients with JIA with active polyarthritis was comparable to adults with RA.

Drug Interactions

Methotrexate: SIMPONI ARIA should be used with MTX for the treatment of RA. Following IV administration, concomitant administration of methotrexate decreases the clearance of SIMPONI ARIA by approximately 9% based on population pharmacokinetics (PK) analysis. In addition, concomitant administration of methotrexate decreases the SIMPONI ARIA clearance by reducing the development of antibodies to golimumab.

Biologic Products for RA, PsA, AS, and pJIA: An increased risk of serious infections has been seen in clinical RA studies of other TNF-blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of SIMPONI ARIA with other biologic products, including abatacept or anakinra, is not recommended. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. The concomitant use of SIMPONI ARIA with biologics approved to treat RA, PsA, AS, and pJIA is not recommended because of the possibility of an increased risk of infection.

Live Vaccines/Therapeutic Infectious Agents: Live vaccines should not be given concurrently with SIMPONI ARIA. Therapeutic infectious agents should not be given concurrently with SIMPONI ARIA. Infants born to women treated with SIMPONI ARIA during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI ARIA in utero is not recommended for 6 months following the mother’s last SIMPONI ARIA infusion during pregnancy.

Cytochrome P450 Substrates: The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.

Use in Specific Populations

No formal study of the effect of renal or hepatic impairment on the PK of golimumab was conducted.

Body Weight: Following intravenous administration, patients with higher body weight tended to have slightly higher serum golimumab concentrations than patients with lower body weights when golimumab was administered on a mg/kg (body weight) basis. However, based on population PK analysis, there were no clinically relevant differences in golimumab exposure following intravenous administration of 2 mg/kg SIMPONI ARIA in adult patients across a range of different body weights. Consistent with the intravenous data in adult patients with RA, population pharmacokinetic analyses for intravenous SIMPONI ARIA in pJIA revealed that there were no clinically relevant differences in golimumab exposure following intravenous administration of 80 mg/m2 SIMPONI ARIA in pediatric patients across a range of age and different body weights. The immune response effect on golimumab clearance in patients with JIA with active polyarthritis was comparable to adults with RA.

Pediatrics: When 80 mg/m2 SIMPONI ARIA was administered intravenously to patients with JIA with active polyarthritis at weeks 0, 4 and every 8 weeks thereafter, serum concentrations reached steady-state by Week 12. With concomitant use of MTX, treatment with 80 mg/m2 SIMPONI ARIA resulted in a mean steady-state trough serum golimumab concentration of approximately 0.5 ± 0.4 mcg/mL and a mean steady-state AUC of 425 ± 125 mcg∙day/mL in patients with JIA with active polyarthritis. Overall, the observed steady-state golimumab trough concentrations in patients with JIA with active polyarthritis were within the range of those observed for adult RA and PsA after administration of SIMPONI ARIA.

Efficacy and Safety

Psoriatic Arthritis: The efficacy of SIMPONI ARIA in pediatric patients with PsA is based on the pharmacokinetic exposure and extrapolation of the established efficacy of SIMPONI ARIA in adult PsA patients. The efficacy and safety of SIMPONI ARIA were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial in 480 patients ≥ 18 years of age with active psoriatic arthritis despite NSAID or DMARD therapy. Previous treatment with a biologic was not allowed. The primary endpoint was the percentage of patients achieving an American College of Rheumatology (ACR) 20 response at Week 14.

Polyarticular Juvenile Idiopathic Arthritis: The efficacy of SIMPONI ARIA in pediatric patients with pJIA is based on the pharmacokinetic exposure and extrapolation of the established efficacy of SIMPONI ARIA in RA patients. Efficacy of SIMPONI ARIA was also assessed in a multicenter, open-label, single-arm study in 127 children (2 to < 18 years of age) with JIA with active polyarthritis despite treatment with MTX for at least 2 months. Efficacy was assessed as supportive endpoints through Week 52. Additional information regarding the efficacy trials can be found in the full prescribing information linked below.

Rheumatoid Arthritis: The efficacy and safety of SIMPONI ARIA were evaluated in one multicenter, randomized, double-blind, controlled trial in 592 patients ≥ 18 years of age with moderately to severely active RA despite concurrent MTX therapy and had not previously been treated with a biologic TNF-blocker. The primary endpoint in Trial RA was the percentage of patients achieving an ACR 20 response at Week 14.

Ankylosing Spondylitis: The efficacy and safety of SIMPONI ARIA were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial in 208 patients ≥ 18 years of age with active ankylosing spondylitis (AS) and inadequate response or intolerance to NSAIDs. The primary endpoint was the percentage of patients achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 16.

Additional information regarding the efficacy trials can be found in the full prescribing information linked below.

The most common adverse reactions (incidence ≥ 3%) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, and rash.


Full prescribing information is available at https://go.usa.gov/xG6Zf.

Visit Drugs@FDA at http://go.usa.gov/cMsjT for prescribing and patient information, approval letters, reviews and other information for FDA-approved drug products, which are often available shortly following approval.

A non-comprehensive list of examples of clinical substrates, inhibitors and inducers for metabolic and transporter system related interactions may be found at https://go.usa.gov/xXY9C.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at https://www.fda.gov/safety/medwatch/default.htm, by faxing (1-800-FDA-0178), or by mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at https://updates.fda.gov/subscriptionmanagement (note: this link does not work with Internet Explorer) and select Clinical Pharmacology Corner under Drugs.

 

We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

Posted by: Shannon Manzi & Matthew Helms on Sep 24, 2020

Hot off the press!  We are happy to share the Pharmacists as Childhood Immunizers Talking Point document created by our Advocacy Committee.  It is important to use our expertise to help support our colleagues who are less comfortable with pediatric care, especially when it comes to vaccinating children.  Education will be a key component in ensuring the gains we are making moving our profession forward will be sustained. 

Please see the document here

Posted by: Lea Eiland on Jun 15, 2020

 

Congratulations to the 2020-2021 SIG Chairs and Vice Chairs. 

SIG

Chair

Vice-Chair

Academia

Amanda Capino

Sarah Smith

Ambulatory Care

Kevin Lonabough and Hannah Pratt

 

Cardiology

Josh Robinson

Amy Kiskaddon

Critical Care

Elizabeth Beckman

Melissa Gervase

Drug Information and Technology

Paul Paratore

Karl Gumpper

Emergency Medicine

Jenny Steinbrenner

Mary Riedy

General Pediatrics

Mindy Parman

Kristi Higgins

GI/Nutrition

Lola Afolabi

Cait Stehling

Hematology/Oncology

Andrew Clark

Jenn Le

Infectious Disease

Sarah Parsons

Mike Raschka

Clinical Leadership/Practice Managers

Courtney Sweet

Sierra Stauber

Medication Safety

Hyun Kim

Casey Moore

Neonatology

Jenni Barnes

Deb Bondi

Neurology (NEW)

Renad Abu-Sawwa

Justin Cole

New Practitioner

Nicole Omecene

Jen Hamner

Obstetrics/Women's Health

Noelle Leung

 

Public Health (NEW)

Cameron McKinzie

Thomas Laudone

Pulmonology

Katie Hobart

 

Residency Program Directors

Kelly Bobo

Kelly Steidl

Do you want to participate in activities and learn from other pediatric pharmacists of similar interest as you? If so, sign up as a member of a PPA Special Interest Group (SIG) today!

PPA has 19 SIGs, with two being NEW this year! Membership in SIGs is complimentary to all PPA members. To join a Special Interest Group eCommunity, Update your Profile via your myPPA page. You sign yourself up via the PPA website. There is no limit to how many you join and no additional charge to join a SIG.

We hope you all will join the SIGs of your interest and network with others!

If you have any questions related to the SIGs, please feel free to contact us.

Thank you!

Lea Eiland, SIG Coordinator Chair
Kalen Manacso, SIG Coordinator Chair-Elect

 

 

Posted by: Matthew Helms on Jun 2, 2020

Brian Eugene Baldwin, 89, of Centennial, CO passed away at Holly Creek Senior Living Community on May 25, 2020.

Mr. Baldwin was an early supporter of the Pediatric Pharmacy Association (previously the Pediatric Pharmacy Advocacy Group). 

Mr. Baldwin had a significant impact on pediatrics. His first company, MPL, inc., founded in 1958 in Chicago, IL was a pioneer in development of inexpensive disposable hypodermic needles. In 1975 Brian co-founded Baxa Corporation, originally located in Northbrook, IL. In 1981, he moved with the company to Colorado, where he would live the remainder of his life. Baxa grew in the next 30 years to have over 700 employees, serving hospitals in over 65 countries. Several of his inventions were key to the success of the company, which specialized in the safe handling and preparation of IV and liquid medications. Brian's inventions were recognized for preventing medication errors and saving lives. 

https://www.legacy.com/amp/obituaries/denverpost/196243738

Posted by: Hanna Phan on May 3, 2020

 

For those able to join on at our 1st virtual conference, the 29th Annual Meeting, thank you for taking time from your busy schedules to participate in quality educational sessions lead by our amazing pediatric pharmacy expert members.

I wanted to take a moment to recognize our 2020 Fellows and Award Recipients – CONGRATULATIONS!!

2020 Fellow (FPPA)

  • Dr. Jeffery Low, Children’s Hospital at Dartmouth 
  • Dr. Brooke Gildon, Southwestern Oklahoma State University
  •  

2020 Presidential Citation Award --- “The KIDs List Team”

  • Dr. Rachel Meyers, Rutgers University
  • Dr. Jennifer Thackary, Memorial Sloan Kettering Cancer Center
  • Dr. Kelly Matson, University of Rhode Island
  • Dr. Christopher McPherson, St Louis Children’s Hospital
  • Dr. Lisa Lubsch, Southern Illinois University Edwardsville
  • Dr. Robert Hellinga, University of New Mexico Hospital
  • Dr. David Hoff, Children’s Hospitals and Clinics of Minnesota
  •  

2020 Spirit of PPA Award

  • Dr. Jennifer Hamner, Colorado Children’s
  • Dr. Norm Fenn, U of Texas-Tyler
  • Dr. Elizabeth Boucher, Concord Hospital
  •  

2020 Outstanding Original Research Paper

  • Dr. Bethany Chalk, Johns Hopkins Hospital
  •  

2020 Christensen Memorial Young Investigator Award

  • Dr. Amy Kiskaddon, Johns Hopkins All Children’s Hospital
  •  

2020 Best Practice Award

  • Dr. Julia Muzzy Williamson, North Dakota State University (presenter)
  • Dr. M Kari Casas, Sanford Children’s Broadway Clinic
  • Dr. May Kamleh, Health Economics and Outcomes Research
  • Dr. Mohamed Mohamed, Sanford Children’s Hospital
  •  

2020 Scholarship in Teaching Award

  • Dr. Lea Eiland, Auburn University (presenter)
  • Dr. Allison Chung, Auburn University
  • Dr. Julaine Fowlin, Auburn University
  •  

2020 Scientific Platforms

  • Dr. Jeremy Stultz, University of Tennessee
  • Hemisha Patel and Alysia Leung (PharmD candidates), Virginia Commonwealth University
  •  

2020 Student Investigator Award

  • Margaret Morales, Hampton University
  •  

2020 John Dice Scholarship

  • Erica Terry, University of Wisconsin
  • Sonya Barich, University of Colorado
  •  

Thank you to the following PPA Board of Director Members, who will be completing their terms in June 2020, for their dedication and service to PPA:

  • Immediate Past President - Dr. Miranda Nelson
  • Director-at-Large – Dr. Bob John
  • Director-at-Large – Dr. Tara Higgins
  •  

I also would like to express my gratitude to, our PPA staff, committees, speakers, moderators, poster and resident presenters -– for your patience, hard work, and passion for pediatric pharmacy. Your efforts are what made this virtual “first” for our association, and our association overall – AMAZING. We are a close and caring community and we should be proud to be part it.

And, THANK YOU from bottom my heart, all PPA members, for the opportunity to serve as your 2019-2020 President. It has truly been an honor and privilege to serve PPA and our profession. I am truly grateful for the friendships, relationships, and collaborations this community provides.

With deep gratitude,

Hanna Phan, PharmD, FCCP, FPPA
2019-2020 PPA President

 

 


Page 1 of 12 • Next